America Movil SAB de CV ADR (AMX)vsGlaxoSmithKline PLC ADR (GSK)
AMX
America Movil SAB de CV ADR
$24.76
+4.52%
COMMUNICATION SERVICES · Cap: $70.61B
GSK
GlaxoSmithKline PLC ADR
$54.71
+3.32%
HEALTHCARE · Cap: $104.12B
Smart Verdict
WallStSmart Research — data-driven comparison
America Movil SAB de CV ADR generates 2789% more annual revenue ($943.64B vs $32.67B). GSK leads profitability with a 17.5% profit margin vs 8.8%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 70/100 (B).
AMX
Strong Buy69
out of 100
Grade: B-
GSK
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.3%
Fair Value
$72.07
Current Price
$24.76
$47.31 discount
Margin of Safety
+66.0%
Fair Value
$172.22
Current Price
$54.71
$117.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Generating 42.7B in free cash flow
Large-cap with strong market position
Every $100 of equity generates 21 in profit
Attractively priced relative to earnings
Strong operational efficiency at 20.1%
Growing faster than its price suggests
Every $100 of equity generates 43 in profit
Earnings expanding 54.7% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Generating 1.5B in free cash flow
Areas to Watch
3.4% revenue growth
4.0% earnings growth
Trading at 72.8x book value
Distress zone — elevated risk
Trading at 10.1x book value
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMX
The strongest argument for AMX centers on Free Cash Flow, Market Cap, Return on Equity. PEG of 1.17 suggests the stock is reasonably priced for its growth.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.5% and operating margin at 18.9%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : AMX
The primary concerns for AMX are Revenue Growth, EPS Growth, Price/Book. Debt-to-equity of 2.53 is elevated, increasing financial risk.
Bear Case : GSK
The primary concerns for GSK are Price/Book, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
AMX profiles as a value stock while GSK is a mature play — different risk/reward profiles.
AMX carries more volatility with a beta of 0.37 — expect wider price swings.
GSK is growing revenue faster at 6.2% — sustainability is the question.
AMX generates stronger free cash flow (42.7B), providing more financial flexibility.
Bottom Line
GSK scores higher overall (70/100 vs 69/100), backed by strong 17.5% margins. AMX offers better value entry with a 67.3% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
America Movil SAB de CV ADR
COMMUNICATION SERVICES · TELECOM SERVICES · USA
Amrica Mvil, SAB de CV provides telecommunications services in Latin America and internationally. The company is headquartered in Mexico City, Mexico.
Visit Website →GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other TELECOM SERVICES Stocks
Want to dig deeper into these stocks?